Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 15/20 | 0.61 |
| ▸ | BCR | P11274 | 12/20 | 0.61 |
| ▸ | KIT | P10721 | 9/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | PRKCA | P17252 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 2/20 | 0.55 |
| ▸ | LDLR | P01130 | 1/20 | 0.55 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 2/20 | 0.53 |
| ▸ | LYN | P07948 | 2/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.53 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | DDX3X | O00571 | 1/20 | 0.52 |
| ▸ | GAK | O14976 | 1/20 | 0.52 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251116 | 0.92 | ABL1 (0.65) | ABL1BCRKITLRRK2PDGFRB | |
| SCHEMBL29551870 | 0.92 | ABL1 (0.65) | ABL1BCRKITLRRK2PDGFRB | |
| SCHEMBL24251186 | 0.91 | ABL1 (0.61) | ABL1BCRKITPDGFRBPDGFRA | |
| SCHEMBL29551726 | 0.91 | ABL1 (0.72) | ABL1BCRKITLRRK2PDGFRB | |
| SCHEMBL24251094 | 0.91 | ABL1 (0.72) | ABL1BCRKITLRRK2PDGFRB | |
| SCHEMBL24251126 | 0.89 | ABL1 (0.57) | ABL1BCRKITLRRK2PDGFRB | |
| SCHEMBL29551395 | 0.88 | ABL1 (0.58) | ABL1BCRKITPDGFRBPDGFRA | |
| SCHEMBL28698135 | 0.88 | ABL1 (0.58) | ABL1BCRKITPDGFRBPDGFRA | |
| SCHEMBL31077579 | 0.87 | ABL1 (0.79) | ABL1BCRKITLRRK2PDGFRB | |
| SCHEMBL29188519 | 0.87 | ABL1 (0.79) | ABL1BCRKITLRRK2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114127065-A | Compounds for the treatment of neurodegenerative diseases and cancer | 鸿仪有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | HONGYI & ASS LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | HONGYI & ASS LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | SNCA, NGF, SLC18A2 | ABL1 695/4885BCR 1219/4885KIT 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.